HPLC-MS/MS METHOD FOR SIMULTANEOUS QUANTIFICATION OF VILDAGLIPTIN, METFORMIN, AND METFORMIN-RELATED COMPOUNDS IN TABLETS
Keywords:
Diabetes, HPLC-MSMS, Metformin, Metformin-related compound, Tablets, VildagliptinAbstract
Objective: The present study developed and validated a high-performance liquid chromatography-tandem mass spectrometry method for simultaneous determination of vildagliptin, metformin, and metformin-related compounds (A, B, and C) in tablets.
Methods: Chromatographic separations were achieved on a C8 column (150 × 4.6 mm, 5 µm particle size) maintained at 25°C. The isocratic mobile phase consisted of acetonitrile/water/formic acid (20:80:0.1, v/v/v), eluted at 800 μL/min. The volume of injection was 20 μL and the electrospray source was operated in positive ion mode.
Results: Data from validation studies demonstrated that the new method was highly selective, sensitive (limits of detection ≤ 0.6 ng/mL), precise (RSD < 5%), and accurate (RE < 5%). All of the calibration curves showed excellent coefficients of correlation (r ³ 0.99) over the ranges of 5‑150 ng/mL for vildagliptin, 250‑2000 ng/mL for metformin, and 2.5‑25 ng/mL for metformin-related compounds A, B, and C. Quantification of these compounds in tablets showed that they contained from 95.2‑101.2% (vildagliptin) and 97‑104.4% (metformin) of the stated level. No metformin-related compounds were detected using this highly sensitive method.
Conclusion: This new method is presented as an alternative approach to the quality control of tablets containing vildagliptin, metformin, and metformin-related compounds.
Downloads
References
Inzucchi S, Bergenstal R, Fonseca V, Gregg E, Mayer-Davis B, Spollett G, et al. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33 Suppl 1:S62-9.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27 5:1047-53.
Setter SM, Iltz JL, Thams J, Campbell RK. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 2003;25(12):2991-3026.
Halimi S, Schweizer A, Minic B, Foley J, Dejager S. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. J Vasc Health Risk Manag 2008;4(3):481-92.
Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahren B, Byiers S, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11(2):157-66.
Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10(1):82-90.
Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, Couturier A, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010;12(9):780-9.
Habib IHI, Kamel MS. Near infra-red reflectance spectroscopic determination of metformin in tablets. Talanta 2003;60(1):185-90.
Wu J, Luo W, Wang XK, Cheng Q, Sun CG, Li H. A new application of WT-ANN method to control the preparation process of metformin hydrochloride tablets by near infrared spectroscopy compared to PLS. J Pharm Biomed Anal 2013;80:186-91.
El-Bagary RI, Elkady EF, Ayoub BM. Spectrophotometric Methods for the Determination of Sitagliptin and Vildagliptin in Bulk and Dosage Forms. Int J Biomed Sci 2011;7(1): 55-61.
Ali MS, Rafiuddin S, Ghori M, Khatri AR. Simultaneous determination of metformin hydrochloride, cyanoguanidine and melamine in tablets by mixed-mode HILIC. Chromatographia 2008;67(7-8):517-25.
Al-Rimawi F. Development and validation of an analytical method for metformin hydrochloride and its related compound (1-cyanoguanidine) in tablet formulations by HPLC-UV. Talanta 2009;79(5):1368-71.
El-Bagary RI, Elkady EF, Ayoub BM. Liquid chromatographic determination of sitagliptin either alone or in ternary mixture with metformin and sitagliptin degradation product. Talanta 2011;85(1):673-80.
El-Bagary RI, Elkady EF, Ayoub BM. Liquid chromatographic methods for the determination of vildagliptin in the presence of its synthetic intermediate and the simultaneous determination of pioglitazone hydrochloride and metformin hydrochloride. Int J Biomed Sci 2011;7(3):201-8.
Tache F, Davis V, Farca A, Medvedovici A. HPLC-DAD determination of Metformin in human plasma using derivatization with p-nitrobenzoyl chloride in a biphasic system. Microchem J 2001;68:13-9.
Latha KP, Ramachandran D. Method development and validation for the simultaneous estimation of vildagliptin and metformin in tablet dosage form by RP-HPLC. Int J Pharm Pharm Sci 2013;5(1):459-63.
Mohammad AM, Elkady EF, Fouad MA. Development and validation of a reversed-phase column liquid chromatographic method for simultaneous determination of two novel gliptins in their binary mixtures with Metformin. Eur J Chem 2012;3(2):152-5.
Varma D, Lakshmana RA, Dinda SC. Simultaneous determination of metformin and vildagliptin in solid dosage form by stability indicating RP-HPLC method. Int Res J Pharm 2013;4(1):122-8.
European Pharmacopoeia. Strasbourg: Council of Europe Vol 2007;2:2370-1.
United States Pharmacopoeia. Rockville: United States Pharmacopoeial Convention 31st ed; 2008. p. 1092.
Validation of analytical procedures: text and methodology. International conference on harmonization, draft revised guidance on Q2 (R1). Current step 4 version. Nov; 2005. p. 6-13.